This may be covered in subsequent posts but I am a little backed up. Although Bernie is not the ranking member, he is a member of the Senate Committee on Health, Education, Labor and Pensions. So he has legitimate oversight responsibilities to monitor the FDA. I dont know if his inquiry will turn the tide for Leronlimab, but Janet Woodcock and her staff better pay attention. Also for fellow Washingtonians, Patty Murray his the Chairwoman of that same committee and would be an appropriate destination to such requests for help.